View Older Stories View More Recent Stories
-
Evercore Comments on Medtronic (MDT)
-
Citi Opens 90d Upside Cat Watch on Medtronic, Inc. (MDT)
-
Leerink Partners: 'We expect MDT to trade higher tomorrow'
-
Medtronic (MDT) gains on RDN NCA proposal
-
Medtronic names Chad Spooner CFO of MiniMed ahead of spinoff
-
Evercore Lists Additions to TAP Outperform List of Life Science & Diagnostic Tools Names
-
Wolfe Research Upgrades Medtronic, Inc. (MDT) to Peerperform
-
Strong AI adoption and monetization to drive the next leg of AI rally, says UBS
-
Medtronic (MDT) appoints Joon Lee to its Board
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
RBC Capital on Medtronic, Inc. (MDT): 'RDN Survey Points To Significant Unlocked Opportunity'
-
Mizuho survey highlights upside in this MedTech stock
-
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
-
Leerink Partners Starts Medtronic, Inc. (MDT) at Outperform
-
Medtronic (MDT) names spinoff diabetes company MiniMed
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Evercore ISI on Boston Scientific (BSX) Read-through: 'This should be a positive for ABT & MDT'
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Medtronic, Inc. (mdt) PT Raised to $92 at Truist Securities
-
Medtronic, Inc. (MDT) PT Lowered to $101 at RBC Capital
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Bernstein on Medtronic, Inc. (MDT): 'Positive Momentum; We Like the Diabetes Split-Off'
-
Evercore ISI Removes Medtronic, Inc. (MDT) from TAP List
-
Medtronic, Inc. (MDT) PT Lowered to $103 at Evercore ISI
-
Medtronic, Inc. (MDT) PT Lowered to $98 at Citi
-
Medtronic (MDT) to separate Diabetes business
-
JPMorgan Reiterates Neutral Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Raises Quarterly Dividend 1.4% to $0.71; 3.3% Yield, 48th consecutive year of an increase in the dividend payment
-
Medtronic (MDT) Tops Q4 EPS by 4c; guides below
-
Medtronic (MDT) to Separate Diabetes Business - WSJ
-
Medtronic (MDT) to Separate Diabetes Business as Stand-Alone Company -- WSJ
-
Medtronic (MDT) May 23 weekly option implied volatility elevated into quarter results
-
Medtronic (MDT) call put ratio 1 call to 3.1 puts into quarter results
-
Needham Reiterates Hold Rating on Medtronic, Inc. (MDT) ahead of earnings
-
JPMorgan Reiterates Neutral Rating on Medtronic, Inc. (MDT) Ahead of Earnings
-
Barclays Reiterates Overweight Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) advances Abbott CGM partnership with FDA submission of interoperable insulin pump
-
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy
-
Piper Sandler on Medtronic, Inc. (MDT): 'Interventional Cardiologist KOL Lukewarm About RDN'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Evercore Adds 7 Names to Tactical Outperform List
-
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
-
Medtronic (MDT) Removes Unused 027 Compatible Pipeline Vantage Embolization Device with Shield Technology, Updates Use Instructions
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Medtronic (MDT) Declares $0.70 Quarterly Dividend; 3% Yield
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
BofA Comments on Trump and Mexico Tariff Delay Impact to Medical Technology Names
-
Citi Upgrades Medtronic, Inc. (MDT) to Buy
-
Medtronic (MDT) earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
-
Medtronic, Inc. (MDT) PT Raised to $95 at UBS

